<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02398357</url>
  </required_header>
  <id_info>
    <org_study_id>CSY-LSX-2015</org_study_id>
    <nct_id>NCT02398357</nct_id>
  </id_info>
  <brief_title>The Effect of Anticoagulation After Endoscopic Therapy in Cirrhotic Patients With Portal Vein Thrombosis</brief_title>
  <official_title>A Zelen-design Randomized Controlled Trial of the Effect of Anticoagulation After Endoscopic Therapy in Cirrhotic Patients With Portal Vein Thrombosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the effect and safety of anticoagulation after endoscopic therapy in cirrhotic
      patients with portal vein thrombosis and to explore whether it can decrease the short-term
      rebleeding rate.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The treatment of cirrhotic patients with PVT (portal vein thrombosis) is clearly recommended
      in guideline now. Several published studies has confirm the effect and safety of
      anticoagulation therapy in cirrhotic patients with PVT.The present studies are most
      observation studies with small sample size and low quality.We need more high-quality research
      such as randomized controlled trials. This is a Zelen-designed randomized controlled trial.
      Patients will randomly enter into two groups:the anticoagulation group or the control group
      and then we will make sure wether their are fond of the group and make decision by
      themselves. The recanalization rate and complications will be analyzed
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recanalization rate of PVT</measure>
    <time_frame>8 weeks</time_frame>
    <description>Patients will receive Doppler ultrasound before enrolled and after followed up for 8 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rebleeding rate</measure>
    <time_frame>8 weeks</time_frame>
    <description>The investigators observe the variceal rebleeding events during 8 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence rate of complications</measure>
    <time_frame>8 weeks</time_frame>
    <description>The investigators observe any severe adverse events caused by anticoagulation therapy or the progress of thrombosis.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Portal Vein Thrombosis</condition>
  <condition>Liver Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No anticoagulation，just routine follow-up</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anticoagulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nadroparin Calcium and Warfarin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nadroparin Calcium and Warfarin</intervention_name>
    <description>Patients will take warfarin started at a dose of 2.5mg/d and with titration of dose to maintain a target INR of 2-3,alone with Nadroparin Calcium 4100IU／d，subcutaneous, when taking endoscopy therapy .</description>
    <arm_group_label>Anticoagulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 18-70 years old;

          -  A clinical, radiological or histologic diagnosis of Liver cirrhosis and portal
             hypertension;

          -  Diagnosed of Portal vein thrombosis;

          -  Capable of understanding the purpose and risks of the study and informed consent to
             participate in the study;

          -  Have undergone endoscopy to prevent variceal rebleeding.

        Exclusion Criteria:

          -  Age &lt;18 or &gt;70 years;

          -  Portal vein thrombosis diagnosed before 6 months;

          -  Patients with signs of acute PVT such as fever，abdominal pain or intestinal
             obstruction，who should be treated immediately;

          -  Pregnant or nursing;

          -  Hepatocellular carcinoma;

          -  Severe cardiopulmonary diseases or concomitant renal insufficiency;

          -  cavernous transformation of the portal vein;

          -  Contradictions to endoscopy;

          -  Contradictions to anticoagulation,such as:allergy to LMWH or warfarin, severe
             uncontrolled hypertension, history of hemorrhagic cerebral vascular accident, recent
             peptic ulcer disease, bacterial endocarditis, ulcerative colitis，sustained platelet
             count &lt; 50 x103/uL);

          -  Taking immunosuppressive agent;

          -  Coagulation disorders other than the liver disease related;

          -  Variceal bleeding failed to control.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shiyao Chen, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Shanghai Zhongshan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shiyao Chen, Professor</last_name>
    <phone>86-13601767310</phone>
    <email>chen.shiyao@zs-hospital.sh.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Zhongshan Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shenxin Lu, Doctor</last_name>
      <phone>86-13611843734</phone>
      <email>08301010239@fudan.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Shiyao Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shenxin Lu</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jian Wang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2015</study_first_submitted>
  <study_first_submitted_qc>March 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2015</study_first_posted>
  <last_update_submitted>December 8, 2015</last_update_submitted>
  <last_update_submitted_qc>December 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Zhongshan Hospital</investigator_affiliation>
    <investigator_full_name>Shiyao Chen</investigator_full_name>
    <investigator_title>department of Gastroenterology</investigator_title>
  </responsible_party>
  <keyword>anticoagulation</keyword>
  <keyword>Zelen-designed randomized controlled trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Nadroparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

